FDA Approves Vafseo for Anemia in Kidney DiseaseMarch 28th 2024
Vafseo, an oral therapy to treat patients with anemia due to chronic kidney, will be available in January 2025. About 40% of patients who could be treated with Vafseo have coverage through Medicare Advantage plans.